The Dual Specificity Protein Kinase TTK (TTK) is a critical enzyme involved in cell division and mitosis. TTK inhibitors are a class of pharmaceutical compounds designed to target and inhibit the activity of TTK, thereby disrupting cell division and suppressing the growth of cancer cells. These inhibitors have shown promising potential in the field of oncology, leading to a growing interest in the Dual Specificity Protein Kinase TTK Inhibitors market.